Home Featured Page 90

Featured

Latest

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

Optimi Health Announces CAD $3,000,000 Senior Debt Financing

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational...

Exploring the Vast Potential of Psychedelic Medicine: A Physician’s Perspective on...

Numinus to Participate in a Water Tower Research Fireside Chat on...

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study...

PT430 – Psychedelics for Eating Disorders, Davos’ House of Psychedelics, and...

Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For...

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its...

FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF TWO CLINICAL TRIALS STUDYING ITS...

EDITOR PICKS

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase...

Psychedelic Policy Briefing: Week of June 22nd, 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelics & Society

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

Optimi Health Announces CAD $3,000,000 Senior Debt Financing

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational...

Exploring the Vast Potential of Psychedelic Medicine: A Physician’s Perspective on...

Numinus to Participate in a Water Tower Research Fireside Chat on...

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study...

PT430 – Psychedelics for Eating Disorders, Davos’ House of Psychedelics, and...

Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For...

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its...

FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF TWO CLINICAL TRIALS STUDYING ITS...

EDITOR PICKS

Psychedelics & Society

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase...

Psychedelic Policy Briefing: Week of June 22nd, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY